Pegylated Interferon Alfa 2a
Sponsors
Kirby Institute, Vertex Pharmaceuticals Incorporated, M.D. Anderson Cancer Center, Shanghai HEP Pharmaceutical Co., Ltd.
Conditions
Chronic Hepatitis BChronic Hepatitis CHepatitis CInfection
Phase 2
Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
CompletedNCT00336479
Start: 2006-06-30End: 2008-02-29Updated: 2014-07-23
Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C
CompletedNCT00372385
Start: 2006-08-31End: 2008-06-30Updated: 2014-07-23
A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)
CompletedNCT00420784
Start: 2007-02-28End: 2009-04-30Updated: 2014-08-05
A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy
CompletedNCT00535847
Start: 2007-10-31End: 2010-02-28Updated: 2014-08-05
A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients
CompletedNCT05244057
Start: 2022-08-23End: 2024-06-24Updated: 2024-07-15
Phase 3
A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)
CompletedNCT00627926
Start: 2008-03-31End: 2010-05-31Updated: 2014-08-08
Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)
TerminatedNCT01821963
Start: 2013-04-30End: 2014-02-28Updated: 2020-09-24